Gene transfer with 'gutted' vectors is associated with persist
Introduction
Adenoviral vectors are being evaluated for somatic gene transfer for treatment of a variety of human diseases. E 1 -deleted or E 1 /E 3 -deleted adenoviral vectors are among the most efficient vehicles for in vivo gene transfer, but their use is hampered by transient transgene expression and hepatotoxicity. Declining transgene expression has generally been attributed to the development of cytotoxic T lymphocyte responses to viral proteins and the resultant destruction of infected cells. [1] [2] [3] [4] [5] [6] Hepatotoxicity after adenoviral gene transfer can occur independently of cellular and humoral immune responses. 7, 8 These limitations of first generation adenoviral vectors have been overcome by the development of helper-dependent 'gut- ted' vectors, which contain no adenoviral coding sequences and induce long-term expression of the transgene in the absence of significant toxicity. [7] [8] [9] [10] The success of 'gutless' vectors has been attributed to the elimination of de novo production of viral proteins leading to a reduction of immune responses and a decrease of direct toxicity of viral proteins.
Limitations of helper-dependent vectors include relatively inefficient production by current methods and the contamination of batches by helper-virus. 11 Attempts to develop helper-virus independent adenoviral vectors for long-term gene transfer in the absence of toxicity have been relatively unsuccessful. Vectors devoid of E 1 /E 3 with additional deletions of E 2a or E 2b did not result in long-term transgene expression and still showed significant toxicity. [12] [13] [14] Gorziglia et al 15 showed that early genes like E 4 were transcribed after transfer with E 1 /E 2a /E 3 -deleted vectors leading to transactivation of the major late promoter, indicating insufficient attenuation of viral gene expression. Studies on E 1 /E 3 /E 4 -deleted vectors have demonstrated dramatically reduced expression of viral proteins, improved transgene DNA persistence and reduced hepatotoxicity. [16] [17] [18] [19] [20] However, persistent transgene expression was generally not obtained due to dependence of the viral promoters used on transactivation by E 4 gene products. 17, 20 In studies on human apo A-I gene transfer in C57BL/6 mice comparing 16 different expression cassettes, 21 we have previously demonstrated that promoter choice and number and position of human apo E enhancers are major determinants of transgene DNA kinetics and hepatotoxicity during the first 35 days after transfer with E 1 -deleted adenoviral vectors. Because the viral backbone was identical for different vectors, the observed large differences of transgene DNA copy number at day 35 did not support the hypothesis that elimination of virus-transduced cells by cytotoxic T-lymphocytes directed against de novo synthesized viral antigens is the predominant mechanism of transgene DNA decline and transient transgene expression after transfer with E 1 -deleted vectors. Furthermore, we hypothesized that toxicity may be caused by a transcriptional squelching mechanism, which is secondary to an interaction of transcription factors encoded by the E 4 region with the expression cassette, leading to a sequestration of a large number of cellular transcription factors. 21 The aims of the present investigation were (1) to develop a helper-virus independent non-toxic adenoviral vector for persistent expression of transgenes after adenoviral transfer in mice; (2) to identify the molecular mechanisms determining transgene DNA kinetics and to examine whether transgene DNA kinetics is dependent on a cellular immune response against viral proteins; (3) to evaluate whether transcriptional squelching may contribute to hepatotoxicity after adenoviral gene transfer. 1, 3, 4 AT are illustrated in Figure 1a . Expression kinetics after transfer with 5 × 10 8 plaque forming units of Ad⌬E 1 AT has been described previously 21 and was similar after transfer with 5 × 10 10 particles in an independent experiment. Peak expression after transfer with Ad⌬E 1 AT was 2.2-fold (P Ͻ 0.01) higher than after transfer with Table 2 illustrates that no biologically significant hepatotoxicity occurred after transfer with Ad⌬E 1, 3, 4 AT, whereas the AUC of ALT levels until day 35 after transfer with the E 1 -deleted vector was 2.6-fold (P Ͻ 0.01) higher compared to the E 1 /E 3 /E 4 -deleted vector. 4 AT, indicating that transgene DNA kinetics and hepatotoxicity are dissociated processes ( Table 2) .
Results

Persistent expression of human apo
Effect of E 4 ORF 3 and of E 4 ORF 4 on transgene DNA kinetics is independent of a cellular immune response
To evaluate whether the effect of E 4 ORF 3 and E 4 ORF 4 on transgene DNA kinetics was dependent on a cellular immune response, human apo A-I expression and human apo A-I transgene DNA kinetics after transfer with Ad⌬E 1, 3, 4 AT ORF3,4+ and Ad⌬E 1, 3, 4 AT were compared in two models of immunodeficiency, C57BL/6 SCID mice and C57BL/6 Rag-1 Ϫ/Ϫ mice. Similarly as previously observed in immunocompetent C57BL/6 mice, human apo A-I expression was unstable after transfer with Ad⌬E 1, 3, 4 AT ORF3,4+ in immunodeficient C57BL/6 SCID mice and C57BL/6 Rag-1 Ϫ/Ϫ mice ( Figure 1c and Table  2 ). Table 2 shows that in C57BL/6 SCID mice, whereas no significant change of human apo A-I transgene DNA copy number occurred between day 35 and 4 months after transfer with Ad⌬E 1, 3, 4 AT, the copy number at 4 months was 23% (P Ͻ 0.05) of this at day 35 after transfer with Ad⌬E 1, 3, 4 AT ORF3,4+. Similarly, transgene DNA copy number at 4 months was 16% (P Ͻ 0.05) of the value at day 35 after transfer with Ad⌬E 1, 3, 4 AT ORF3,4+ in C57BL/6 Rag-1 Ϫ/Ϫ mice, but no change was observed after transfer with Ad⌬E 1,3,4 AT ( Table 2) . Together, these data indicate that the effect of E 4 ORF 3 and E 4 ORF 4 on transgene DNA kinetics is independent of a cellular immune response.
Effect of E 4 region on hepatotoxicity and on transgene DNA kinetics occurs in trans
Comparison of the AUC of ALT levels until day 35 after transfer with Ad⌬E 1 AT and Ad⌬E 1, 3, 4 AT indicates that the E 4 region plays a critical role in hepatotoxicity after adenoviral transfer, in agreement with previously published data. 22 To evaluate whether the effect of the E 4 region on hepatotoxicity and on transgene DNA kinetics occurs in trans, 2.5 × 10 10 or 5 × 10 10 particles of Ad⌬E 1 Nul, containing no expression cassette and 5 × 10 10 particles of Ad⌬E 1, 3, 4 AT were co-injected. Figure 2a shows that the peak expression was 1.7-fold (P Ͻ 0.01) and 2.5-fold (P Ͻ 0.01) higher after transfer with 2. (Figure 3b ; Table 2 ).
Effect of E 4 ORF 3 on transgene DNA kinetics occurs partially in trans
As shown in Table 2 , E 4 ORF 3 plays an important role in transgene DNA kinetics, but does not play a critical role in hepatotoxicity. To evaluate directly whether the effect of E 4 ORF 3 occurs in trans, 5 × 10 10 particles of Ad⌬E 1, 3, 4 Nul ORF3+ and 5 × 10 10 particles of Ad⌬E 1, 3, 4 AT were co-injected. As illustrated in Figure 2b , peak expression of human apo A-I in this co-injection experiment was not significantly different than after transfer with Ad⌬E 1, 3, 4 AT ORF3+ and 3.4-fold (P Ͻ 0.01) higher than after transfer with Ad⌬E 1, 3, 4 AT, but expression was unstable leading to a 3.7-fold (P Ͻ 0.01) decline of expression between day 10 and 4 months. After transfer with 5 × 10 10 particles of Ad⌬E 1, 3, 4 Nul ORF3+ plus 5 × 10 10 particles of Ad⌬E 1, 3, 4 AT, human apo A-I transgene DNA copy number at 4 months was 57% (P Ͻ 0.05) of the copy number at day 35, whereas after transfer with 5 × 10 10 particles of Ad⌬E 1, 3, 4 AT ORF3+, the copy number at day 35 was 26% of this at 4 months, indicating a less pronounced decline of human apo A-I transgene DNA after transfer in the co-injection experiment ( Figure 4a and Table 2 ) and was also observed after transfer with Ad⌬E 1,3,4 C-II ORF3,4+ ( Figure 4a and Table 2 ). Gene transfer with Ad⌬E 1,3,4 C-II was not associated with a decline of transgene expression and DNA in the first 35 days after transfer, but the transgene DNA copy numbers at 4 months (2.4 ± 0.29) and at 6 months (1.3 ± 0.32) were 71% (NS) and 38% (P Ͻ 0.05) of the copy number at day 35 (3.4 ± 0.24). The human apo A-I transgene DNA copy number at 6 months after transfer with Ad⌬E 1,3,4 C-II was 2.3-fold (P Ͻ 0.05) lower than after transfer with Ad⌬E 1, 3, 4 AT.
After transfer with 5 × 10 10 particles of Ad⌬E 1 AT5', a more rapid decline of human apo A-I expression and transgene DNA copy number was observed compared with Ad⌬E 1 AT, similarly as previously observed after transfer with 5 × 10 8 plaque forming units ( Figure 4b and Table 2 ). After transfer with Ad⌬E 1,3,4 AT5', human apo A-I levels decreased 1.9-fold (P Ͻ 0.01) between peak expression at day 6 and day 35 and further decreased 4.6-fold (P Ͻ 0.01) between day 35 and 4 months. The human apo A-I transgene DNA copy number after transfer with Ad⌬E 1,3,4 AT5' was 6.2-fold (P Ͻ 0.01) and 22-fold (P Ͻ 0.01) higher at day 35 and at 4 months, respectively, than after transfer with Ad⌬E 1 AT5'. The human apo A-I transgene DNA copy number after transfer with Ad⌬E 1,3,4 AT5' was not significantly different and 1.5-fold (P = 0.05) lower at day 35 and 4 months, respectively, than after transfer with Ad⌬E 1, 3, 4 AT. Because human apo A-I expression levels declined 4.6-fold (P Ͻ 0.01) between day 35 and 4 months after transfer with Ad⌬E 1,3,4 AT5', whereas human apo A-I transgene DNA copy number at 4 months was 52% (P Ͻ 0.01) of this at day 35, we determined human apo A-I mRNA levels in the liver. For comparison, the human apo A-I mRNA level was determined at day 35 and 4 months after transfer with Ad⌬E 1, 3, 4 AT. The human apo A-I mRNA level declined 6.3-fold between day 35 (1.8 ± 0.30) and 4 months (0.29 ± 0.048) after transfer with Ad⌬E 1,3,4 AT5' and was 11-fold (P Ͻ 0.01) lower at 4 months than after transfer with Ad⌬E 1,3,4 AT (3.1 ± 0.37). These data indicate that the decrease of the human apo A-I expression levels after transfer with Ad⌬E 1,3,4 AT5' is due both to accelerated DNA decline and to attenuation of the potency of the expression cassette. Gene transfer with Ad⌬E 1,3,4 C-II and Ad⌬E 1,3,4 AT5' was not associated with biologically significant hepatotoxicity ( Table 2 ). The AUC of ALT levels until day 35 was 3.6-fold (P Ͻ 0.01) and 5.2-fold (P Ͻ 0.01) lower after transfer with Ad⌬E 1,3,4 C-II and Ad⌬E 1, 3, 4 AT5', respectively, than after transfer with the respective E 1 -deleted vectors.
These data indicate that the expression cassette is a determinant of transgene DNA kinetics independent of the effect of E 4 ORF 3 and E 4 ORF 4 and independent of hepatotoxicity, providing direct evidence for episomal instability as a determinant of transgene DNA kinetics and for the role of the expression cassette in determining episomal instability.
Discussion
The main findings of the present study are: (1) that gene transfer with an E 1 /E 3 /E 4 -deleted adenoviral vector con-taining the hAAT.gA-I.4xapoE expression cassette results in persistent expression of human apo A-I; (2) that transgene DNA kinetics in the liver after adenoviral transfer is critically dependent on the presence or absence of E 4 ORF 3 and E 4 ORF 4, whereas other E 4 ORFs play only a minor role; (3) that a cellular immune response does not play a significant role in transgene DNA kinetics if the transgene product is not immunogenic; (4) that in the absence of E 4 , long-term transgene DNA kinetics is dependent on the specific expression cassette used, providing direct evidence for episomal instability as the prime determinant of long-term transgene DNA levels; and (5) that transcriptional squelching may contribute to toxicity involving E 4 gene products.
Previous attempts to establish long-term transgene expression after transfer with E 1 /E 4 -or E 1 /E 3 /E 4 -deleted vectors have been hampered by markedly reduced expression from the viral CMV [17] [18] [19] [20] and RSV promoters 16 or the ubiquitously active eukaryotic phosphoglycerate kinase promoter. 23 Transactivation by the E 4 region 17 or more specifically by E 4 ORF 3 in the liver and E 4 ORF 3 together with E 4 ORF 4 or E 4 ORF 6 and E 4 ORF 6/7 in the lung 20 was shown to be a prerequisite for expression from the CMV promoter. However, whereas stable persistence of transgene DNA after transfer with E 1 /E 4 -deleted vectors has been demonstrated previously, 16 transgene DNA was unstable after transfer with an E 1 /E 2a /E 3 /E 4 -deleted vector encoding factor VIII and retaining E 4 ORF 3. 24 Instability of transgene DNA after transfer with vectors containing E 4 ORF 3 was also demonstrated in the present study, indicating that deletion of E 4 ORF 3 and the identification of expression cassettes which are independent of transactivation by E 4 ORF 3, are absolute prerequisites for long-term expression. Gao et al 25 demonstrated ␤-galactosidase expression for 60 days after transfer with an E 1 /E 4 -deleted vector containing a LacZ minigene driven by the chicken ␤-actin promoter with enhancer sequences from the cytomegalovirus immediate-early gene sequences. Wang et al 26 showed ␤-galactosidase expression driven from the murine phosphoglycerate kinase promoter for 3 months after transfer with an E 1 /E 4 -deleted vector retaining ORF 4. However, expression in these studies declined already in the first 2 months. In contrast, transfer with Ad⌬E 1,3,4 AT showed expression and transgene DNA kinetics which are similar as observed after transfer with 'gutted' vectors. [8] [9] [10] [11] 27 Peak expression after transfer with Ad⌬E 1,3,4 AT was approximately two-fold lower than after transfer with Ad⌬E 1 AT. Lower peak expression was also observed after transfer with E 1 /E 3 /E 4 -deleted vectors containing the C-II.gA-I.4xapoE or the 4xapoE.hAAT.gA-I expression cassettes compared with the respective E 1 -deleted vectors. Results obtained after transfer with Ad⌬E 1,3,4 AT ORF3+ and after co-injection with Ad⌬E 1,3,4 AT and Ad⌬E 1, 3, 4 Nul ORF3+ indicate that E 4 ORF 3 induces higher peak expression of human apo A-I in trans. The less pronounced effect of E 4 ORF 3 after transfer with Ad⌬E 1 AT or in the co-injection experiment of Ad⌬E 1 Nul and Ad⌬E 1, 3, 4 AT is likely to be due to an attenuation of the effect of E 4 ORF 3 by E 4 ORF 4, since peak expression was very similar after transfer with Ad⌬E 1, 3, 4 28 Together, these data indicate that peak expression levels obtained after transfer with E 1 -deleted vectors are significantly higher than expression levels obtained with 'gutted' or E 1 /E 3 /E 4 -deleted vectors.
An important observation in the present study is that the decline of transgene DNA is independent of hepatotoxicity and independent of a cellular immune response against viral epitopes. We have previously shown that human apo A-I gene transfer in C57BL/6 mice was not associated with the development of antibodies against human apo A-I and that human apo A-I did not induce T-lymphocyte proliferation ex vivo. 29 The absence of immune responses against the transgene product is a necessary prerequisite to study in vivo the role of cellular immune responses against viral epitopes in transgene DNA kinetics. Alexander-Miller et al 30 provided direct evidence that activity of cytotoxic T-lymphocytes in vitro does not accurately reflects activity in vivo, indicating that the potential role of cytotoxic T-lymphocytes in the destruction of transduced cells in vivo cannot be extrapolated from chromium release assays in vitro using different effector:target ratios. Therefore, the role of cellular immune responses against viral epitopes in transgene DNA kinetics after adenoviral transfer can only be evaluated in vivo in adequate models of immunodeficiency, provided that the vectors encode a non-immunogenic transgene products. Therefore, the demonstration of similar DNA kinetics in C57BL/6 SCID and C57BL/6 Rag-1 Ϫ/Ϫ mice compared with immunocompetent C57BL/6 mice indicates that there is no significant role for cellular immune responses against viral epitopes in transgene DNA kinetics in the liver.
Notwithstanding the widely assumed role of cellular immune responses against viral epitopes in transgene DNA kinetics in the liver, [1] [2] [3] [4] [5] [6] some previous studies were not in line with this hypothesis. 31, 32 Wadsworth et al 31 demonstrated that intravenous administration of an E 1 -deleted adenoviral vector expressing human ␣ 1 anti-trypsin in C57BL/6 mice stimulated an Ad-specific cellular immune response, but that this response failed to abolish vectordirected gene expression in vivo. Even when Ad-specific cytotoxic T-lymphocytes were boosted, there was no impact on human ␣ 1 anti-trypsin expression. Experiments with psoralen-treated UV-cross-linked adenoviral vectors have shown that lysis of target cells in vitro occurred as efficiently as after transfer with a biologically active vector, indicating that de novo viral protein synthesis is not required to obtain a positive cytotoxic T-lymphocyte assay in vitro. 33 Therefore, positive cytotoxic T-lymphocyte assays in vitro may also occur in the absence of de novo protein expression after transfer with 'gutted' vectors and are compatible with long-term transgene expression and transgene DNA persistence. Also, because 'gutted' vectors and different E 1 /E 3 /E 4 -deleted vectors used in the present study do not contain sequences encoding the E 3 gene product gp19K, which can inhibit cytotoxic T-lymphocyte killing by trapping MHC class I molecules in the endoplasmic reticulum, 34 gp 19K cannot be a confounder for the absence of in vivo cellular immune responses against viral epitopes mediating transgene DNA kinetics. The discrepancy between the present study and previous studies is likely to be due to the use of a xenogenic, but not immunogenic, transgene product in the present study and the use of xenogenic and immunogenic transgene products in previous studies. [1] [2] [3] [4] [5] [6] 35, 36 However, an effect of the nature of the transgene product (secreted in the present study, intracellular or cell-surface associated in previous studies) on transgene DNA kinetics can not entirely be excluded.
Gene transfer experiments with Ad⌬E 1, 3, 4 AT ORF3+ and the co-injection experiment with Ad⌬E 1, 3, 4 AT and Ad⌬E 1, 3, 4 Nul ORF3+ indicate that E 4 ORF 3 induces a decline of transgene DNA in the absence of major hepatotoxicity and that this effect occurs at least partially in trans. Therefore, transgene DNA kinetics is dissociated both from a cellular immune response against viral proteins and from hepatotoxicity. E 4 ORF 3, like E 4 ORF 6, is involved in the regulation of the maturation of the 28 kb late primary transcript. 37 However, it has also been demonstrated that E 4 ORF 3 causes a drastic redistribution of nuclear domain 10 (ND 10), also known as promyelocytic oncogenic domains (PODs) or Kremer bodies, from spherical nuclear bodies into fibrous structures. [38] [39] [40] During this process, nuclear proteins like Sp-100 and NDP55 relocate from ND 10 to the viral inclusion bodies, where during wild-type viral infection DNA replication and late RNA transcription occur. Therefore, it is tempting to speculate that E 4 ORF 3 affects the nuclear sublocalization of the recombinant adenoviral DNA molecule and the nuclear proteins interacting with the recombinant adenoviral DNA molecule and hereby determines the rate of nuclear degradation of the episomal DNA. However, transgene DNA kinetics after transfer with Ad⌬E 1, 3, 4 C-II and Ad⌬E 1, 3, 4 AT5' indicate that, in the absence of E 4 ORF 3, the promoter and the position of apo E enhancers remain a determinant of transgene DNA decay. This finding is a reiteration of similar observations previously made with E 1 -deleted vectors in a shorter time-frame of 35 days and may be explained by the effect of promoters and enhancers on the chromatin structure of the episomal DNA molecule. 41 The effects of promoter and position of apo E enhancers on episomal DNA stability indicate the importance of the design of the expression cassette in the development of helper-virus independent adenoviral vectors for long-term overexpression of transgenes.
One important caveat in the interpretation of transgene DNA data is that the present study was focused on transgene DNA kinetics in the liver, one of the most important target organs for adenoviral gene transfer. Transgene DNA kinetics may be dependent on the transduced celltype. Long-term stable erythropoietin expression following intramuscular injection of an E 1 -deleted vector has been demonstrated in rodents and non-human primates, indicating that the role of E 4 ORF 3 on transgene DNA kinetics is likely to be dependent on the cell-type. 42, 43 We have previously shown that hepatotoxicity after transfer with E 1 -deleted vectors was critically dependent on the promoter, the number of apo E enhancers and 5' or 3' position of the apo E enhancers 21 and suggested that toxicity may be caused by a transcriptional squelching mechanism, which is secondary to an interaction of E 4 encoded transcription factors with the expression cassette leading to a sequestration of a large amount of cellular coactivators and to cellular toxicity. Christ et al 22 1, 3, 4 AT. This was in agreement with the a priori hypothesis, because Ad⌬E 1 Nul does not contain an expression cassette and Ad⌬E 1, 3, 4 AT does not encode for the factors involved in transactivation and squelching. When both vectors are co-injected, toxicity is equivalent after transfer with Ad⌬E 1 AT5'. Obviously, the occurrence of minor elevations of ALT levels after transfer with 10 11 particles of Ad⌬E 1 Nul indicates that transcriptional squelching is not the sole mechanism of toxicity, although this toxicity may also be caused by modulation of cellular transcription by E 4 gene products.
In conclusion, we have constructed a non-toxic E 1 /E 3 /E 4 -deleted helper-virus independent adenoviral vector resulting in persistent expression of human apo A-I. Transgene DNA kinetics is critically dependent on E 4 ORF 3 and E 4 ORF 4, independent of cellular immune responses against viral epitopes and independent of hepatotoxicity. E 1 /E 3 /E 4 -deleted vectors containing transgenes under control of the hAAT promoter in combination with four copies of the human apo E enhancer may be suitable for hepatocyte-specific overexpression of transgenes after gene transfer.
Materials and methods
Viral vectors
Nucleotide numbering throughout this paper is according to Chroboczek et al. 44 E 1 -deleted vectors (Ad⌬E 1 ) contain an E 1 -deletion from nucleotide 454 to 3333. The generation of the E 1 -deleted vectors AdE 1 ⌬hAAT.gA-I.4xapoE, AdE 1 ⌬C-II.gA-I.4xapoE, AdE 1 ⌬.4xapoE.hAAT.gA-I and AdAdE 1 ⌬Nul has been described previously. 21 The nomenclature of these E 1 -deleted vectors in the present paper is abbreviated to Ad⌬E 1 AT, Ad⌬E 1 C-II, Ad⌬E 1 AT5' and Ad⌬E 1 Nul, respectively.
21 Ad⌬E 1 C-II and Ad⌬E 1 AT contain the human apo C-II and the human ␣ 1 -antitrypsin promoter, respectively, in front of the genomic human apo A-I sequence and four copies of the liver-specific human apo E enhancer. Ad⌬E 1 AT5' contains four copies of the human apo E enhancer 5' of the human ␣ 1 -antitrypsin promoter and the genomic human apo A-I sequence. Ad⌬E 1 Nul does not contain an expression cassette. For construction of E 1 /E 3 /E 4 -deleted adenoviral vectors, viral genomes were constructed as infectious plasmids by homologous recombination in Escherichia coli as described by Chartier et al. 45 The E 1 and E 3 deletions extend from nucleotides 459 to 3511 and from nucleotides 28 592 to 30 470, respectively. 20, 22 The specific E 4 deletions have been described previously. 22 Briefly, E 4 deleted vectors (Ad⌬E 1,3,4 ) were used for homologous recombination. After release of the viral genomes from the recombinant plasmids by PacI digestion, 5 g of DNA was transfected into the complementation cell line 293-E 4 ORF 6/7. 46 Virus propagation and purification were as described previously. 46, 47 The nomenclature of viral vectors with different E 4 deletions used in the present investigation is represented in Table 1 . The viral particle concentration was calculated by measuring the optical density of the viral DNA content. 48 Human apo A-I ELISA Human apo A-I levels were determined by sandwich ELISA as described previously. 29 Briefly, polystyrene microtiter plates (Elscolab, Kruisbeke, Belgium) were coated with a rabbit anti-human apo A-I polyclonal antibody. The polyclonal rabbit anti-human apo A-I antibody was generated in the Center for Molecular and Vascular Biology by injecting 10 11 plaque forming units of an E 1 -deleted vector containing the CMV promoter in front of the human apo A-I gene in New Zealand White rabbits. Boosting in these rabbits was perfomed three times by subcutaneous injection of 50 g of human apo A-I in complete Freund adjuvants. Diluted plasma samples (1:50 000; 1:100 000, 1:200 000, 1:400 000) were added to the wells for 2 h. After washing, a 1:15 000 dilution of the murine monoclonal antibody A 4 H 4 A 7 , generated in the Center for Molecular and Vascular Biology and conjugated with peroxidase (Sigma, St Louis, MO, USA), was added to the wells for 2 h. Peroxidase reaction was performed by adding H 2 O 2 and ortho-phenylene-diamine. Finally, absorbance was measured at 492 nm.
Quantification of human apo A-I transgene DNA in the liver
Total DNA was extracted from liver tissue as described previously. 49 Human apo A-I DNA was quantified using quantitative real-time PCR and the human apo A-I DNA copy number was normalized to the copy number of the Prion Protein (PrP) housekeeping gene. The sequence of primers and probes has been published previously. 29 Quantification of human apo A-I mRNA in the liver Total RNA was isolated from mouse liver using TRIzol Reagent (Invitrogen, Merelbeke, Belgium). RNA (10 g) was treated with DNAse (Pharmacia Biotech, Uppsala, Sweden) and subsequently reverse transcribed using Superscript II RT (Invitrogen, Carlsbad, CA, USA) at 42°C for 50 min in the presence of 0.5 mM dNTPs, 0.01 M DTT, 1 × first strand buffer and 250 ng pd(N) 6 Random Hexamer (Pharmacia). Human apo A-I cDNA was measured using quantitative real-time PCR and the human apo A-I cDNA level was normalized to the level of the glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) housekeeping gene cDNA. The sequence of primers and probes has been published previously. 29 
Determination of alanine aminotransferase activity
To determine alanine aminotransferase (ALT) activity, 80 l plasma was diluted in isotonic saline buffer (10 mM Tris-HCl pH 7.4, 137mM NaCl, 5 mM KCl, 1mM MgCl 2 ) to a final volume of 200 l. ALT activity was measured in the modular PPP analyser (Roche) of the laboratory Gene Therapy of the University Hospital of Leuven, according to the instructions of the manufacturer and is expressed in international units per liter (IU/l).
Animal experiments
All experimental procedures were approved by the Institutional Animal Care and Research Advisory Committee. Recombinant adenoviruses were administered by tail vein injection into 2-to 3-month-old female C57BL/6 mice. Each viral dose was given in a final volume of 300 l. C57BL/6 mice were obtained from the specific pathogen free animal facility of the Center for Molecular and Vascular Biology and C57BL/6 SCID and C57BL6 Rag-1 Ϫ/Ϫ mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Experimental groups consisted of at least 10 animals for each recombinant vector. Blood was obtained by puncture of the retro-orbital plexus of at least five animals at each time-point for each group. Anticoagulation was performed with 1/10 volume of 4% trisodiumcitrate and plasma was obtained by centrifugation at 3000 r.p.m. for 10 min.
Statistical analysis
All data are expressed as mean ± standard error of the mean (s.e.m.). Comparison of human apo A-I levels, human apo A-I transgene DNA copy number or human apo A-I cDNA levels were performed by non-parametric Mann-Whitney test using the INSTAT V2.05a statistical program (Graph Pad Software, San Diego, CA, USA). Differences in liver enzymes were compared by Student's t test. A two sided P value of less than 0.05 was considered statistically significant. The area under the curve of human apo A-I and ALT levels was calculated by using NCSS 2000 (NCSS Statistical Software, Kaysville, UT, USA).
